People · Operator
Named in public records as an officer, director or promoter · active 2012–2020 · Biotechnology, Pharmaceuticals, Other, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aligos Therapeutics, Inc. | — | Biotechnology | Series D+ | $282.2M | $940.9M | 2019 |
| vTv Therapeutics Inc. | — | Pharmaceuticals | Series C | $80.5M | $502.3M | 2017 |
| FS OneEquity Partners Co. L.P. | — | Other | Series C | $55.7M | $53.3M | 2016 |
| Amee Inc | — | Other Technology | Series A | $10.4M | $83.2M | 2012 |
John Fry at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John Fry on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Albert Wenger | 1 | 20 |
| Jack Nielsen | 1 | 13 |
| Paul Meister | 1 | 12 |
| Michael Kelly | 1 | 11 |
| Mark Jacobsen | 1 | 9 |
| Peter Hirth | 1 | 7 |
| Steven Cohen | 1 | 6 |
| Peter Moldt | 1 | 6 |
| Tim Murphy | 1 | 6 |
| Craig Parker | 1 | 5 |
| Richard Vague | 1 | 5 |
| Toby Coppel | 1 | 4 |
| Michael Yi | 1 | 4 |
| Jeffrey Kindler | 1 | 3 |
| Carole Neuchterlein | 1 | 3 |
| Lawrence Blatt | 1 | 3 |
| Kathleen Glaub | 1 | 3 |
| Howard Weiner | 1 | 3 |
| Paul J. Sekhri | 1 | 2 |
| Leonid Beigelman | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.